Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Hematologic MalignanciesLeukemiaMyelodysplastic SyndromesMyeloid MetaplasiaLymphoma
Interventions
DRUG

ridaforolimus

AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks

Trial Locations (8)

10021

New York Presbyterian Hospital, Weill College of Cornell University, New York

19111

Jeane's Hospital of TUHS, Philadelphia

27705

Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic, Durham

44718

Gabrail Cancer Center, Canton

60637

University of Chicago Hospitals, Section of Hematology/Oncology, Chicago

63110

Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place, St Louis

77030

MD Anderson Cancer Center, Houston

08903

The Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ariad Pharmaceuticals

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY